Orally effective drugs for kala-azar (visceral leishmaniasis): Focus on miltefosine and sitamaquine

Journal of Association of Physicians of India

Volumn 51, Issue JUL, 2003, Pages 686-690

  Sangraula, H ^a   Sharma, K K ^a   Rijal, S ^a   Dwivedi, S ^a   Koirala, S ^a  

^a BP Koirala Institute of Health Sciences ^*  (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE; 8-AMINOQUINOLINE; AMINOQUINOLINE DERIVATIVE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; MILTEFOSINE; PHOSPHORYLCHOLINE;

ANIMAL; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; INDIA; LEISHMANIA DONOVANI; ORAL DRUG ADMINISTRATION; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; AMINOQUINOLINES; ANIMALS; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE;

EID: 2842531646     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
2. Desjeux P. Leishmaniasis: public health aspects and control. Clin Dermatol 1996;14:417-23.
3. Herwaldt BL. Miltefosine-the long-awaited therapy for visceral leishmaniasis? Editorial. New Engl J Med 1999;341:1840-2.
4. Moral CM. Reaching maturity-25 years of the TDR. Parasitology today 2000;16:522-6 (from the World Health Report 2000: TDR Strategy 2000-2005, Geneva: WHO. Website:http://who.int/tdr/about/strategy).
5. Berman J. US food and drug administration approval of ambisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999;28:42-8.
6. Roberts LJ, Handman E, Foote SJ. Leishmaniasis. Br Med J 2000;321:801-4.
7. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998;56:1009-18.
8. Jha TK, Olliaro P, Thakur CPN, Kanyok TP, Singhania BL, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. Br Med J 1998;316:1200-4.
9. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single agent therapy for Colombian cutaneous leishmaniasis. Trans Royal Soc Trop Med Hyg 1994;88:695-8.
10. Anonymous. In: Tropical disease research: Progress 1997-98. 14th programme report. Geneva: UNDP/World Bank/ WHO special programme for research and training in tropical diseases (TDR). 1999:39-41.
11. Berman JD, Lee LS. Activity of oral drugs against Leishmania tropica in human macrophages in vitro. Am J Trop Med Hyg 1983;32:947-51.
12. Wali JP, Aggarwal P, Gupta U, Saluja S, Singh S. Ketoconazole in treatment of visceral leishmaniasis. Lancet 1990;336:810-1.
13. Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis. Lancet 1990;336:1582-3.
14. Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala azar with oral fluconazole. Lancet 1996;348:614.
15. Lal SK, Lal R, Lal S, Lal R, Lal BN. Experience with roxithromycin in visceral leishmaniasis in North Bihar. J Assoc Physicians India 1996;44:615-7.
16. Das VNR, Ranjan A, Sinha AN, Verma N, Lal CS, et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India 2001;49:609-13.
17. Rege NN. Visceral leishmaniasis: Can we dream its eradication? J Assoc Physicians India 2001;49:605-8.
18. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36:2633-6.
19. Croft SL, Showdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypansoma cruzei and Trypanosoma brucei. J Antimicrob Chemother 1996;38:1041-7.
20. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992;36:1630-4.
21. Le Fichoux Y, Rousseau D, Ferrua B, et al. Short- and long term efficacy of hexadecyl- phosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 1998;42:654-8.
22. Eibl H. Hexadecylphosphocholine: a new selective antitumour drug. Cancer Treat Rev 1990;17:233-42.
23. Danhauser-Riedl S, Drozd A, Zafferani M, et al. Phase I study of weekly miltefosine (hexadecyl-phosphocholine) in cancer patients. Onkologie 1991;14:392-400.
24. Burk K, David M, Junge K, Sindermann H. Overview on the clinical development of miltefosine solution (Miltex® for the treatment of cutaneous breast cancer. Drugs Today 1994;30 (Suppl B):59-72.
25. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998;352:1821-3.
26. Sundar S, Gupta SB, Makharia MK, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999;93:589-97.
27. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. New Engl J Med 1999;341:1795-1800.
28. Sundar S, Mhakharia MK, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000;31:1110-3.
29. Mattock N. Public/Private/Partnership: developing oral treatment for visceral leishmaniasis. WHO-DRNewsNo60. Website:http://www.who.int/tdr/ publications/tdrnews/news60/miltefosine/html
30. R) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg 1999;93:85-90.
31. Sherwood JA, Gachihi GS, Muigai RK, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994;19:1034-9.
32. Sherwood JA. Miltefosine for visceral leishmaniasis (Letter). New Engl J Med 2000;342:895.
33. Herwaldt BL. Miltefosine for visceral leishmaniasis (Reply to Letter). New Engl J Med 2000;342:895.
34. Anonymous. Report on the consultative meeting on leishmania/HIV Co-infection, Rome September 6-7, 1994. Geneva: World Health Organization, 1995. (WHO/LEISH/95-35).